新華醫療(600587.SH)：全資子公司華佗國際參與設立的惠遠華檢完成工商登記
格隆匯 9 月 11日丨新華醫療(600587.SH)公告，公司全資子公司華佗國際發展有限公司(以下簡稱“華佗國際”)近日收到山東惠遠華檢醫療投資合夥企業(有限合夥)(以下簡稱“惠遠華檢”)的通知，其已於2020年9月10日完成工商登記。
為推進新華醫療在體外診斷行業的戰略佈局，新華醫療全資子公司華佗國際擬與山東國惠改革發展基金合夥企業(有限合夥)(以下簡稱“國惠改革基金”)、威士達醫療設備(上海)有限公司(以下簡稱“上海威士達”)共同作為有限合夥人參與設立惠遠華檢，由中民惠遠(山東)股權投資管理有限公司(以下簡稱“中民惠遠”)作為普通合夥人暨執行事務合夥人。各方已簽署《投資合作協議》，惠遠華檢總募集規模為人民幣30010萬元，其中國惠改革基金認繳出資15000萬元人民幣，認繳比例為49.99%；華佗國際認繳出資9000萬元人民幣，認繳比例為29.99%；上海威士達認繳出資6000萬元人民幣，認繳比例為19.99%；中民惠遠認繳出資10萬元人民幣，認繳比例為0.03%。國惠改革基金、華佗國際、上海威士達認繳出資額將按照惠遠華檢合夥協議約定分批實繳到位。
新華醫療的全資子公司華佗國際近日收到惠遠華檢的通知，其已於2020年9月10日完成工商登記，並取得淄博市市場監督管理局頒發的營業執照。具體工商登記信息如下：
1、公司名稱：山東惠遠華檢醫療投資合夥企業(有限合夥)
2、社會統一信用代碼：91370300MA3TYUML8W
3、公司類型：有限合夥企業(港、澳、台投資)
4、執行事務合夥人：中民惠遠(山東)股權投資管理有限公司(委派代表張珊珊)
5、成立日期：2020年9月10日
6、主要經營場所：山東省淄博市高新區魯泰大道51號高分子材料創新園A座0615
7、經營範圍：一般項目：以自有資金從事投資活動(除依法須經批准的項目外，憑營業執照依法自主開展經營活動)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
